Darya-Varia Laboratoria (IDX:DVLA) - Share price, News & Analysis

DVLA fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	0/6
Past Performance	2/6
Financial Health	5/6
Dividends	5/6

DVLA Stock Overview

PT Darya-Varia Laboratoria Tbk engages in the manufacture and trading of pharmaceutical products and cosmetics in Indonesia and internationally.

Rewards

Trading at 81.1% below our estimate of its fair value

Risk Analysis

Unstable dividend track record

Darya-Varia Laboratoria Competitors

Kalbe Farma

IDX:KLBF

Rp75.1t

Kimia Farma (Persero)

IDX:KAEF

Rp8.4t

Indofarma

IDX:INAF

Rp3.5t

Phapros

IDX:PEHA

Rp844.2b

Price History & Performance

Summary of all time highs, changes and price drops for Darya-Varia Laboratoria
Historical stock prices
Current Share Price	Rp2,440.00
52 Week High	Rp3,400.00
52 Week Low	Rp2,250.00
Beta	-0.0098
1 Month Change	-11.27%
3 Month Change	-18.12%
1 Year Change	5.63%
3 Year Change	8.93%
5 Year Change	16.75%
Change since IPO	187.06%

Shareholder Returns

	DVLA	ID Pharmaceuticals	ID Market
7D	-0.4%	-0.4%	-1.0%
1Y	5.6%	1.5%	18.2%

Return vs Industry: DVLA exceeded the ID Pharmaceuticals industry which returned 1.5% over the past year.

Return vs Market: DVLA underperformed the ID Market which returned 18.2% over the past year.

Price Volatility

Is DVLA's price volatile compared to industry and market?
DVLA volatility
DVLA Average Weekly Movement	3.7%
Pharmaceuticals Industry Average Movement	3.7%
Market Average Movement	6.3%
10% most volatile stocks in ID Market	12.2%
10% least volatile stocks in ID Market	3.0%

Stable Share Price: DVLA is less volatile than 75% of ID stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: DVLA's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1976	1,239	Jose Romana	https://www.darya-varia.com

PT Darya-Varia Laboratoria Tbk engages in the manufacture and trading of pharmaceutical products and cosmetics in Indonesia and internationally. It operates in three segments: Prescription Drugs, Consumer Health Products, and Export and Toll Manufacturing Services. It provides various prescription and consumer health products in antibiotic, antiparasit, antiseptic, anti-fungal, cough and cold, cardiology, central nervous system, gastro-hepatology, somatic, vitamin and food supplement, women healthcare, ear healthcare, and derma medic areas.

Darya-Varia Laboratoria Fundamentals Summary

How do Darya-Varia Laboratoria's earnings and revenue compare to its market cap?
DVLA fundamental statistics
Market Cap	Rp2.73t
Earnings (TTM)	Rp146.73b
Revenue (TTM)	Rp1.90t

18.6x

P/E Ratio

1.4x

P/S Ratio

Is DVLA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
DVLA income statement (TTM)
Revenue	Rp1.90t
Cost of Revenue	Rp905.76b
Gross Profit	Rp995.13b
Other Expenses	Rp848.41b
Earnings	Rp146.73b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	131.01
Gross Margin	52.35%
Net Profit Margin	7.72%
Debt/Equity Ratio	1.7%

How did DVLA perform over the long term?

See historical performance and comparison

Dividends

4.6%

Current Dividend Yield

85%

Payout Ratio

Valuation

Is Darya-Varia Laboratoria undervalued compared to its fair value and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: DVLA (IDR2440) is trading below our estimate of fair value (IDR12887.84)

Significantly Below Fair Value: DVLA is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: DVLA is good value based on its PE Ratio (18.6x) compared to the ID Pharmaceuticals industry average (20.9x).

PE vs Market: DVLA is good value based on its PE Ratio (18.6x) compared to the ID market (18.9x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DVLA's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: DVLA is good value based on its PB Ratio (2x) compared to the ID Pharmaceuticals industry average (2.4x).

Future Growth

How is Darya-Varia Laboratoria forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

15.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Darya-Varia Laboratoria has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Darya-Varia Laboratoria performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

3.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: DVLA has high quality earnings.

Growing Profit Margin: DVLA's current net profit margins (7.7%) are lower than last year (8.9%).

Past Earnings Growth Analysis

Earnings Trend: DVLA's earnings have grown by 3.9% per year over the past 5 years.

Accelerating Growth: DVLA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: DVLA had negative earnings growth (-9.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (12.8%).

Return on Equity

High ROE: DVLA's Return on Equity (10.6%) is considered low.

Financial Health

How is Darya-Varia Laboratoria's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: DVLA's short term assets (IDR1,526.7B) exceed its short term liabilities (IDR595.1B).

Long Term Liabilities: DVLA's short term assets (IDR1,526.7B) exceed its long term liabilities (IDR110.0B).

Debt to Equity History and Analysis

Debt Level: DVLA has more cash than its total debt.

Reducing Debt: Insufficient data to determine if DVLA's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: DVLA's debt is well covered by operating cash flow (1894.3%).

Interest Coverage: DVLA earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet

Dividend

What is Darya-Varia Laboratoria current dividend yield, its reliability and sustainability?

Dividend Score

4/6

Dividend Score 4/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

4.59%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: DVLA's dividend (4.59%) is higher than the bottom 25% of dividend payers in the ID market (1.12%).

High Dividend: DVLA's dividend (4.59%) is in the top 25% of dividend payers in the ID market (4.1%)

Stability and Growth of Payments

Stable Dividend: DVLA's dividend payments have been volatile in the past 10 years.

Growing Dividend: DVLA's dividend payments have increased over the past 10 years.

Earnings Payout to Shareholders

Earnings Coverage: At its current payout ratio (85.5%), DVLA's payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (35.8%), DVLA's dividend payments are well covered by cash flows.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

7.3yrs

Average board tenure

CEO

Jose Romana (59 yo)

1.58yrs

Tenure

Mr. Jose Sumpaico Romana has been President Director and Director at PT Darya-Varia Laboratoria Tbk since October 20, 2020. Mr. Romana served as Vice President Director and Director at PT Darya-Varia Labor...

Board Members

Experienced Board: DVLA's board of directors are considered experienced (7.3 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/19 00:00
End of Day Share Price	2022/05/19 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31